In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Faux foie gras firm forms foodie panel
In Paris, cultivated meat startup Gourmey has formed what it claims is the culinary industry’s first-ever advisory board dedicated to cultivated meat.
The panel...
Celleste Bio secures $4.5 million for cell-cultured cocoa
In Israel, cell cultured cocoa startup Celleste Bio has raised $4.5 million in a seed funding round. The funds will boost the company's research...
Wrapped up: Origami inspires paperboard packaging solution
In Finland, researchers from VTT and Aalto University are applying origami, the ancient Japanese art of paper folding, to the plastics waste crisis.
Led...